MCID: BCT006
MIFTS: 30

Bacterial Conjunctivitis

Categories: Eye diseases, Immune diseases

Aliases & Classifications for Bacterial Conjunctivitis

MalaCards integrated aliases for Bacterial Conjunctivitis:

Name: Bacterial Conjunctivitis 12 15 17 74
Conjunctivitis, Bacterial 45
Purulent Conjunctivitis 12

Classifications:



External Ids:

Disease Ontology 12 DOID:9700
MeSH 45 D003234
NCIt 51 C53656
SNOMED-CT 69 17482009
ICD10 34 H10.0
UMLS 74 C0009768

Summaries for Bacterial Conjunctivitis

MalaCards based summary : Bacterial Conjunctivitis, also known as conjunctivitis, bacterial, is related to conjunctivitis and purpura fulminans. An important gene associated with Bacterial Conjunctivitis is TTC37 (Tetratricopeptide Repeat Domain 37). The drugs Estradiol and Ethinyl Estradiol have been mentioned in the context of this disorder. Affiliated tissues include eye and testes.

Related Diseases for Bacterial Conjunctivitis

Diseases in the Conjunctivitis family:

Acute Conjunctivitis Chronic Conjunctivitis
Bacterial Conjunctivitis

Diseases related to Bacterial Conjunctivitis via text searches within MalaCards or GeneCards Suite gene sharing:

# Related Disease Score Top Affiliating Genes
1 conjunctivitis 11.6
2 purpura fulminans 9.9
3 purpura 9.9
4 iridocyclitis 9.9
5 ophthalmomyiasis 9.8
6 trachoma 9.8
7 blepharoconjunctivitis 9.8
8 haemophilus influenzae 9.8
9 acute conjunctivitis 9.8
10 blepharitis 9.8

Graphical network of the top 20 diseases related to Bacterial Conjunctivitis:



Diseases related to Bacterial Conjunctivitis

Symptoms & Phenotypes for Bacterial Conjunctivitis

Drugs & Therapeutics for Bacterial Conjunctivitis

Drugs for Bacterial Conjunctivitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 103)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2 50-28-2 5757
2
Ethinyl Estradiol Approved Phase 4,Phase 3,Phase 2 57-63-6 5991
3
Polyestradiol phosphate Approved Phase 4,Phase 3,Phase 2 28014-46-2
4
Moxifloxacin Approved, Investigational Phase 4,Phase 3,Phase 2 354812-41-2, 151096-09-2 152946
5
Norgestimate Approved, Investigational Phase 4,Phase 3,Phase 2 35189-28-7 6540478
6
Gatifloxacin Approved, Investigational Phase 4,Phase 3,Phase 2 112811-59-3 5379
7
Azithromycin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 83905-01-5 55185 447043
8
Permethrin Approved, Investigational Phase 4,Phase 2 52645-53-1 40326
9
Albendazole Approved, Vet_approved Phase 4,Phase 3,Not Applicable 54965-21-8 2082
10
Ivermectin Approved, Investigational, Vet_approved Phase 4,Phase 3,Not Applicable 70288-86-7 6474909
11
Tetracycline Approved, Vet_approved Phase 4 60-54-8 5353990
12 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
13 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
14 Ophthalmic Solutions Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
15 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
16 Contraceptive Agents Phase 4,Phase 3,Phase 2
17 Contraceptives, Oral Phase 4,Phase 3,Phase 2
18 Topoisomerase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
19 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1
20 Estradiol 17 beta-cypionate Phase 4,Phase 3,Phase 2
21 Estradiol 3-benzoate Phase 4,Phase 3,Phase 2
22 Norgestimate, ethinyl estradiol drug combination Phase 4,Phase 3,Phase 2
23 Contraceptives, Oral, Combined Phase 4,Phase 3,Phase 2
24 Antiprotozoal Agents Phase 4,Phase 3,Not Applicable
25 Antimitotic Agents Phase 4,Phase 3,Not Applicable
26 Antiparasitic Agents Phase 4,Phase 3,Not Applicable
27 Antitubercular Agents Phase 4,Phase 3,Phase 2
28 Anthelmintics Phase 4,Phase 3,Not Applicable
29
Dipivefrin Approved Phase 3,Phase 2 52365-63-6 3105
30
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 2 50-02-2 5743
31
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3,Phase 2 1177-87-3
32
Tobramycin Approved, Investigational Phase 3 32986-56-4 5496 36294
33
Zinc Approved, Investigational Phase 3 7440-66-6 32051
34
Polymyxin B Approved, Vet_approved Phase 3 1404-26-8
35
Bacitracin Approved, Vet_approved Phase 3 1405-87-4 439542 10909430
36
Neomycin Approved, Vet_approved Phase 3 1404-04-2 8378
37
Ganciclovir Approved, Investigational Phase 3 82410-32-0 3454
38
Besifloxacin Approved Phase 3,Phase 2,Phase 1 141388-76-3
39
Levofloxacin Approved, Investigational Phase 3,Phase 2,Phase 1 100986-85-4 149096
40
Ofloxacin Approved Phase 3,Phase 2,Phase 1 82419-36-1 4583
41
Povidone-iodine Approved Phase 3,Not Applicable 25655-41-8
42
Iodine Approved, Investigational Phase 3,Not Applicable 7553-56-2 807
43
Povidone Approved Phase 3,Not Applicable 9003-39-8
44
Vancomycin Approved Phase 3 1404-90-6 441141 14969
45
Pentetic acid Approved Phase 3 67-43-6
46
Edetic Acid Approved, Vet_approved Phase 3 62-33-9, 60-00-4 6049
47
Mannitol Approved, Investigational Phase 3 69-65-8 453 6251
48
Sodium Citrate Approved, Investigational Phase 3 68-04-2
49
Calcium polycarbophil Approved Phase 3 126040-58-2
50
Diethylcarbamazine Approved, Investigational, Vet_approved Phase 3 90-89-1 3052

Interventional clinical trials:

(show top 50) (show all 77)
# Name Status NCT ID Phase Drugs
1 Study of the Progression of Bacterial Conjunctivitis Symptoms Upon Antibiotic Treatment Completed NCT00798577 Phase 4 Vigamox Ophthalmic Solution;BSS placebo
2 Topical Treatment of Bacterial Conjunctivitis and Its Effect on Microbial Flora Completed NCT00312338 Phase 4 VIGAMOX
3 A Study to Evaluate the Safety and Efficacy of Gatifloxacin for the Treatment of Bacterial Conjunctivitis Completed NCT00464438 Phase 4 gatifloxacin;moxifloxacin 0.5% eye drops
4 Partnership for Rapid Elimination of Trachoma Completed NCT00792922 Phase 4 Azithromycin;Azithromycin
5 A Trial of Non-absorbable Versus Absorbable Sutures for Trichiasis Surgery Completed NCT00522860 Phase 4
6 Impact of Water and Health Education Programs on Trachoma and Ocular C. Trachomatis in Niger Completed NCT00348478 Phase 4
7 Effect of Intensive Fly Control on Trachoma and Ocular Chlamydia Infection in Tanzania Completed NCT00347763 Phase 4
8 Study of Three Alternatives for Mass Treatment in Trachoma Villages of Tanzania Completed NCT00347607 Phase 4
9 Tripartite International Research for the Elimination of Trachoma Completed NCT01202331 Phase 4 mass treatment with oral azithromycin
10 Impact of Two Alternative Dosing Strategies for Trachoma Control in Niger Completed NCT00618449 Phase 4 Azithromcyin;Azithromycin
11 Trachoma Amelioration in Northern Amhara (TANA) Completed NCT00322972 Phase 4 Mass treatment with oral azithromycin to an entire community
12 Trachoma Elimination Follow-up Completed NCT00221364 Phase 4 Mass treatment with oral azithromycin to an entire village
13 Sanitation, Water, and Instruction in Face-washing for Trachoma Recruiting NCT02754583 Phase 4 Azithromycin;Tetracycline;Albendazole
14 Trachoma Elimination Study by Focused Antibiotic (TESFA) Not yet recruiting NCT03523156 Phase 4 Azithromycin mass treatment;Azithromycin targeted treatment
15 Kebele Elimination of Trachoma for Ocular Health Not yet recruiting NCT03335072 Phase 4 Azithromycin
16 Cluster RCT of Co-administration Azithromycin, Albendazole & Ivermectin Not yet recruiting NCT03570814 Phase 4 Administration of Albendazole on Day 1;Administration of Ivermectin on Day 1;Administration of Azithromycin on Day 1;Administration of Azithromycin on Day 15
17 Azithromycin in Control of Trachoma II Withdrawn NCT00286026 Phase 4 Azithromycin
18 Safety Study of Combined Azithromycin, Ivermectin and Albendazole for Trachoma and Lymphatic Filariasis Withdrawn NCT01903057 Phase 4 azithromycin;ivermectin;albendazole;placebo
19 Effectiveness Comparison Between the Drugs TOBRACORT® and TOBRADEX® in Reducing the Signs and Symptoms of Acute Bacterial Conjunctivitis Unknown status NCT01227915 Phase 3 Tobracort;Tobradex
20 Efficacy Maxinom® And Maxitrol® in Reducing The Signs And Symptoms Of Acute Bacterial Conjunctivitis Unknown status NCT01227863 Phase 3 MAXINOM®;Maxitrol®
21 Evaluate the Use of Ganciclovir Gel 0.3% for the Treatment of Conjunctivitis Caused by Adenovirus Unknown status NCT01600365 Phase 3 Ophthalmic gel (placebo);Ganciclovir
22 A Study to Determine if 0.6% ISV-403 is Safe and Effective in the Treatment of Bacterial Conjunctivitis. Completed NCT00347932 Phase 3 ISV-403;Vehicle
23 An Evaluation of the Safety and Efficacy of Moxifloxacin Ophthalmic Solution 0.5% ((VIGAMOX®) Versus Ofloxacin Ophthalmic Solution 0.3% in the Treatment of Bacterial Conjunctivitis in Chinese Patients Completed NCT01573910 Phase 3 Moxifloxacin ophthalmic solution, 0.5%;Ofloxacin ophthalmic solution, 0.3%
24 Treatment of Bacterial Conjunctivitis With SHP640 Compared to PVP-Iodine and Placebo Completed NCT03004924 Phase 3 SHP640;PVP-I 0.6%;Placebo
25 Safety and Efficacy of Vancomycin Ophthalmic Ointment in Patients With Moderate to Severe Bacterial Conjunctivitis Completed NCT02432807 Phase 3 Vancomycin 1.1%;Placebo
26 Study of Efficacy of Levofloxacin 0.5% Ophthalmic Solution Administered Three Times a Day for Bacterial Conjunctivitis Completed NCT00565123 Phase 2, Phase 3 0.5% levofloxacin eye drops;0.5% levofloxacin eye drops
27 AL-15469A for the Treatment of Bacterial Conjunctivitis Completed NCT00331916 Phase 3 quinolone
28 AL-15469A for the Treatment of Bacterial Conjunctivitis Completed NCT00332293 Phase 3 Moxifloxacin Alternative Formulation Ophthalmic Solution 0.5%;Moxifloxacin hydrochloride ophthalmic solution 0.5% as base
29 Evaluation of Clinical and Microbial Efficacy and Safety of AzaSite Compared to Tobramycin for Bacterial Conjunctivitis (C-01-401-004) Completed NCT00105469 Phase 3 AzaSite;Tobramycin
30 Evaluation of Clinical and Microbial Efficacy and Safety of AzaSite Compared to Vehicle for Bacterial Conjunctivitis (C-01-401-003) Completed NCT00105534 Phase 3 AzaSite
31 Efficacy of Besifloxacin Ophthalmic Suspension in the Treatment of Bacterial Conjunctivitis Completed NCT00972777 Phase 2, Phase 3 Besifloxacin;Vehicle (Placebo)
32 A Study to Investigate the Safety and Efficacy of BOL-303224 in the Treatment of Bacterial Conjunctivitis Completed NCT00348348 Phase 3 Besifloxacin;Moxifloxacin solution
33 Moxifloxacin AF Ophthalmic Solution for Treatment of Bacterial Conjunctivitis Completed NCT00759148 Phase 3 Moxifloxacin Alternative Formulation (AF) Ophthalmic Solution 0.5%
34 A Study of the Safety and Efficacy of Gatifloxacin in Patients With Bacterial Conjunctivitis Completed NCT00509873 Phase 3 Gatifloxacin 0.5% eye drops;placebo eye drops
35 A Study of the Safety and Efficacy of Gatifloxacin in Patients With Bacterial Conjunctivitis Completed NCT00518089 Phase 3 Gatifloxacin 0.5% eye drops;placebo eye drops
36 Clinical Efficacy and Safety of T1225 Versus Tobramycin 0.3 % Eye Drops in the Treatment of Purulent Bacterial Conjunctivitis of Children. Completed NCT01155999 Phase 3 T1225;Tobramycin
37 Efficacy and Safety of T1225 1.5% Versus Tobramycin 0.3 % in the Treatment of Purulent Bacterial Conjunctivitis Completed NCT00357773 Phase 3 Azithromycin (T1225)
38 Safety of Besivance™ (Besifloxacin Ophthalmic Suspension) 0.6% Compared to Vehicle Completed NCT01175590 Phase 3 Besivance;Vehicle
39 Safety/Efficacy of Antibiotic Steroid Combination in Treatment of Blepharitis and/or Keratitis and/or Conjunctivitis Completed NCT00732446 Phase 3 Moxifloxacin and Dexamethasone combined;Moxifloxacin;Dexamethasone
40 Prevention of Bacterial Infections in Newborn Completed NCT01800942 Phase 3 Azithromycin and Placebo
41 Efficacy and Safety of 2 Dosing Regimens of T1225 Eye Drops 1.5% Versus Oral Azithromycin in Treatment of Trachoma Completed NCT00356720 Phase 3 Azithromycin
42 Safety of Co-administration of IDA and Azithromycin for NTDs ( ComboNTDs ) Completed NCT03676140 Phase 3 Albendazole on Day 1;Ivermectin on Day 1;Diethylcarbamazine on day 1;Azithromycin on Day 1;Azithromycin on Day 8
43 Clinical Trial of Eye Prophylaxis in the Newborn Completed NCT00000120 Phase 3 Erythromycin Ointment;Silver Nitrate Drops
44 Treatment of Adenoviral Conjunctivitis With SHP640 Compared to Placebo Recruiting NCT02998554 Phase 3 SHP640;Placebo
45 Treatment of Adenoviral Conjunctivitis With SHP640 Compared to Povidone-iodine (PVP-I) and Placebo Recruiting NCT02998541 Phase 3 SHP640;PVP-I 0.6%;Placebo
46 Efficacy of the Ophthalmic Pazufloxacin 0.6% for Bacterial Conjunctivitis, Compared to Gatifloxacin 0.3%. Active, not recruiting NCT03696342 Phase 3 Pazufloxacin;Zymar
47 Clinical and Microbial Efficacy of Besifloxacin Ophthalmic Suspension, 0.6% in the Treatment of Bacterial Conjunctivitis Terminated NCT01740388 Phase 3 Besifloxacin;Vehicle
48 Besifloxacin Ophthalmic Suspension Verses Gatifloxacin Ophthalmic Solution in Neonates With Bacterial Conjunctivitis Terminated NCT01330355 Phase 3 Besivance;Gatifloxacin
49 Antibiotic Steroid Combination Compared With Individual Administration in the in the Treatment of Ocular Inflammation and Infection Withdrawn NCT01721694 Phase 3 azithromycin 1.5%/Loteprednol 0,5% + placebo;azithromycin 1.5% + Loteprednol 0,5% (separately)
50 Nepal Elimination of Trachoma Study Withdrawn NCT02176057 Phase 2, Phase 3 Azithromycin

Search NIH Clinical Center for Bacterial Conjunctivitis

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cochrane evidence based reviews: conjunctivitis, bacterial

Genetic Tests for Bacterial Conjunctivitis

Anatomical Context for Bacterial Conjunctivitis

MalaCards organs/tissues related to Bacterial Conjunctivitis:

42
Eye, Testes

Publications for Bacterial Conjunctivitis

Articles related to Bacterial Conjunctivitis:

(show top 50) (show all 166)
# Title Authors Year
1
Correction to: Efficacy and Safety of 0.6% Pazufloxacin Ophthalmic Solution Versus Moxifloxacin 0.5% and Gatifloxacin 0.3% in Subjects with Bacterial Conjunctivitis: A Randomized Clinical Trial, by Baiza-Durán, L., Olvera-Montaño, O., Mercado-Sesma, A.R., and Oregon-Miranda, A.A. J Ocul Pharmacol Ther 2018;34(3):250-255. DOI: 10.1089/jop.2017.0056. ( 30699060 )
2019
2
Bacterial conjunctivitis in childhood: etiology, clinical manifestations, diagnosis, and management. ( 29380707 )
2018
3
Contact lenses with dual drug delivery for the treatment of bacterial conjunctivitis. ( 29960036 )
2018
4
Antibodies to Conserved Surface Polysaccharides Protect Mice Against Bacterial Conjunctivitis. ( 29847658 )
2018
5
Efficacy and Safety of 0.6% Pazufloxacin Ophthalmic Solution Versus Moxifloxacin 0.5% and Gatifloxacin 0.5% in Subjects with Bacterial Conjunctivitis: A Randomized Clinical Trial. ( 29624493 )
2018
6
Management of Bacterial Conjunctivitis in Children-Preferred Practice Pattern in Northern Greece. ( 30157160 )
2018
7
Analysis of the drug therapy of gatifloxacin and levofloxacin in the treatment of acute bacterial conjunctivitis. ( 30203775 )
2018
8
Topical Antibiotics for Clinical and Microbiologic Cure of Bacterial Conjunctivitis. ( 30421517 )
2018
9
Epidemiology of bacterial conjunctivitis in chinchillas (Chinchilla lanigera): 49 cases (2005 to 2015). ( 28276116 )
2017
10
Besifloxacin Ophthalmic Suspension 0.6% Compared with Gatifloxacin Ophthalmic Solution 0.3% for the Treatment of Bacterial Conjunctivitis in Neonates. ( 28078599 )
2017
11
Resistant Infantile Bacterial Conjunctivitis in Egypt: A Microbiology Study. ( 29131910 )
2017
12
Preparation and evaluation of novel chitosan: gelrite ocular system containing besifloxacin for topical treatment of bacterial conjunctivitis: scintigraphy, ocular irritation and retention assessment. ( 28708424 )
2017
13
Adult bacterial conjunctivitis: resistance patterns over 12 years in patients attending a large primary eye care centre in the UK. ( 29354693 )
2017
14
A chronological study of the bacterial pathogen changes in acute neonatal bacterial conjunctivitis in southern China. ( 28950852 )
2017
15
Patient demographic and microbiology trends in bacterial conjunctivitis in children. ( 29247795 )
2017
16
Neonatal Bacterial Conjunctivitis in Korea in the 21st Century. ( 28002109 )
2016
17
Acute bacterial conjunctivitis - antibiotic susceptibility and resistance to commercially available topical antibiotics in Nepal. ( 28242882 )
2016
18
A 3-day regimen with azithromycin 1.5% eyedrops for the treatment of purulent bacterial conjunctivitis in children: efficacy on clinical signs and impact on the burden of illness. ( 25945033 )
2015
19
Preparation and in vitro/in vivo evaluation of antimicrobial ocular in situ gels containing a disappearing preservative for topical treatment of bacterial conjunctivitis. ( 25886078 )
2015
20
Deep subconjunctival injection of gentamicin for the treatment of bacterial conjunctivitis in macaques (Macaca mulatta and Macaca fascicularis). ( 25693106 )
2015
21
Gatifloxacin 0.5% Administered Twice Daily for the Treatment of Acute Bacterial Conjunctivitis in Patients One Year of Age or Older. ( 25244402 )
2014
22
Efficacy and safety of azithromycin 1.5% eye drops in paediatric population with purulent bacterial conjunctivitis. ( 24526744 )
2014
23
The role of besifloxacin in the treatment of bacterial conjunctivitis. ( 24566460 )
2014
24
An evaluation of the reclassification of ophthalmic chloramphenicol for the management of acute bacterial conjunctivitis in community pharmacies in Western Australia. ( 24841453 )
2014
25
External ophthalmomyiasis caused by Oestrus ovis misdiagnosed as bacterial conjunctivitis. ( 23780871 )
2013
26
Epidemiological study of hospital-acquired bacterial conjunctivitis in a level III neonatal unit. ( 23766676 )
2013
27
A new diagnostic index for bacterial conjunctivitis in primary care. A re-derivation study. ( 24256320 )
2013
28
Identification of causative pathogens in eyes with bacterial conjunctivitis by bacterial cell count and microbiota analysis. ( 23246122 )
2013
29
A case of recalcitrant bacterial conjunctivitis. ( 24555257 )
2013
30
The safety of besifloxacin ophthalmic suspension 0.6 % used three times daily for 7 days in the treatment of bacterial conjunctivitis. ( 24142473 )
2013
31
Besifloxacin ophthalmic suspension 0.6% administered twice daily for 3 days in the treatment of bacterial conjunctivitis in adults and children. ( 22420526 )
2012
32
Bacterial conjunctivitis. ( 22348418 )
2012
33
Gatifloxacin ophthalmic solution for treatment of bacterial conjunctivitis: safety, efficacy and patient perspective. ( 23650458 )
2012
34
Besifloxacin ophthalmic suspension, 0.6%: a novel topical fluoroquinolone for bacterial conjunctivitis. ( 22729919 )
2012
35
Antibiotics versus placebo for acute bacterial conjunctivitis. ( 22972049 )
2012
36
Bacterial conjunctivitis: a review of therapies and approaches. ( 23189448 )
2012
37
Besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis patients with Pseudomonas aeruginosa infections. ( 23233796 )
2012
38
Microbiological etiology and susceptibility of bacterial conjunctivitis isolates from clinical trials with ophthalmic, twice-daily besifloxacin. ( 22644963 )
2012
39
Bacterial conjunctivitis in children: antibacterial treatment options in an era of increasing drug resistance. ( 20724317 )
2011
40
Moxifloxacin 0.5% ophthalmic solution: in bacterial conjunctivitis. ( 21175242 )
2011
41
Treatment of bacterial conjunctivitis in children. ( 21323206 )
2011
42
Bacterial conjunctivitis in children: a current review of pathogens and treatment. ( 21897142 )
2011
43
Microbiological efficacy of a new ophthalmic formulation of moxifloxacin dosed twice-daily for bacterial conjunctivitis. ( 21681652 )
2011
44
Efficacy and tolerability of besifloxacin ophthalmic suspension 0.6% administered twice daily for 3 days in the treatment of bacterial conjunctivitis: a multicenter, randomized, double-masked, vehicle-controlled, parallel-group study in adults and children. ( 21397770 )
2011
45
Integrated analysis of three bacterial conjunctivitis trials of besifloxacin ophthalmic suspension, 0.6%: microbiological eradication outcomes. ( 22034555 )
2011
46
High proportion of nontypeable Streptococcus pneumoniae isolates among sporadic, nonoutbreak cases of bacterial conjunctivitis. ( 21988450 )
2011
47
Integrated analysis of three bacterial conjunctivitis trials of besifloxacin ophthalmic suspension, 0.6%: etiology of bacterial conjunctivitis and antibacterial susceptibility profile. ( 22034556 )
2011
48
Bacterial conjunctivitis and of antibiotics in Dhulikhel Hospital-Kathmandu University Hospital. ( 22610873 )
2011
49
Besifloxacin ophthalmic suspension: emerging evidence of its therapeutic value in bacterial conjunctivitis. ( 23861618 )
2011
50
Clinical use of gatifloxacin ophthalmic solution for treatment of bacterial conjunctivitis. ( 21573098 )
2011

Variations for Bacterial Conjunctivitis

Expression for Bacterial Conjunctivitis

Search GEO for disease gene expression data for Bacterial Conjunctivitis.

Pathways for Bacterial Conjunctivitis

GO Terms for Bacterial Conjunctivitis

Sources for Bacterial Conjunctivitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....